AssetMark Inc
PCRX icon

AssetMark Inc’s Pacira BioSciences PCRX Stock Holding History

AssetMark Inc’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$786 Hold
31
– – ﹤0.01% 3193
2026
Q1 		$701 Hold
31
– – ﹤0.01% 3113
2025
Q4 		$802 Hold
31
– – ﹤0.01% 2996
2025
Q3 		$799 Buy
+31
New +$761 ﹤0.01% 2833
2018
Q1 		– Sell
-3
Closed – – 1831
2017
Q4 		$0 Buy
+3
New +$119 ﹤0.01% 2060

Other funds holding PCRX

GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

AssetMark Inc's PCRX Position: Q2 2026 in Review

AssetMark Inc held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 31 shares worth $786. The position accounts for ﹤0.01% of the portfolio, ranked #3193.

AssetMark Inc first reported a position in PCRX in Q4 2017 and has held it in 5 quarters since. The position peaked at $802 in Q4 2025. 81 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • AssetMark Inc held 31 shares of Pacira BioSciences worth $786 as of Q2 2026.
  • AssetMark Inc left its Pacira BioSciences share count unchanged in Q2 2026.
  • Pacira BioSciences made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3193 holding.
  • AssetMark Inc first reported a position in Pacira BioSciences in Q4 2017 and has held it in 5 quarters since.
  • AssetMark Inc's Pacira BioSciences position peaked at $802 in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.